Dulaglutide Research

Chen Q, Chen T, Lin W, Chen X

To conduct a systematic, multi-dimensional clinical evaluation of five long-acting glucagon-like peptide-1 receptor agonists (GLP-1RAs) available in China, providing evidence-based guidance for clinical preference and institutional formulary selection.This study was structured according to the "A...

Ulrich FS, Napoli N, Nielsen MF, Burden AM

Real-world medication use varies across clinical trial and healthcare settings; therefore, we evaluated GLP-1 receptor agonist (GLP-1RA) persistence and dose titration among adults with type 2 diabetes in UK primary care, stratified by agent, obesity status, cardiovascular disease (CVD) history, ...

Kahles F, Birkenfeld AL, Marx N

The incretin hormone glucagon-like peptide-1 (GLP-1) exerts potent effects on glucose metabolism, prompting the development of therapeutic strategies that enhance activity of the GLP-1 receptor (GLP-1R) pathway. Inhibitors of dipeptidyl peptidase 4 (DPP-4) prolong the half-life of endogenous GLP-...

Patil S, Jha N, Jha MK

Substance use disorders (SUDs) are widely prevalent and associated with high morbidity and mortality. Current treatments have limited efficacy and there are no United States Food and Drug Administration (FDA)-approved treatments for several SUDs (such as methamphetamine, cocaine, and cannabis use...

Zhou Y, Jiang W

Shevchouk O, Edvardsson CE, Ericson M, Blid Sköldheden S, Zhang Q, Dreher Nabinger D et al.

Beyond the metabolic effects induced by long- and short-acting glucagon-like peptide-1 receptor (GLP-1R) agonists, they modulate reward-related behaviors by acting on brain regions including lateral septum (LS) and neural pathways involving the nucleus tractus solitarii (NTS). While the short-act...

Kuoni S, Caviglia S, Dolder A, Gawinecka J, Ochsenbein-Kölble N, Simões-Wüst AP et al.

The use of glucagon-like peptide-1 (GLP-1) receptor agonists by young populations is rapidly increasing worldwide, thereby exposing more women of childbearing age. Dulaglutide, a long-acting GLP-1 receptor agonist designed to bind to the neonatal Fc receptor (FcRn) and approved for type 2 diabete...

Kubota-Okamoto S, Kubota S, Tsuchida H, Liu Y, Banno S, Imaizumi T et al.

Dipeptidyl peptidase-4 (DPP-4) inhibitors enhance circulating levels of biologically intact incretins, yet the relative contribution of glucose-dependent insulinotropic polypeptide (GIP) to their metabolic effects remains incompletely understood. While glucagon-like peptide-1 (GLP-1) has long bee...

Hsiao FC, Hsu TJ, Hsieh YJ, Tung YC, Chen DY, Lin CP et al.

Patients with diabetes and a history of major adverse limb events (MALEs) are at an increased risk of cardiovascular and limb-related complications; however, effective glucose-lowering therapies for secondary prevention in this population are limited.To evaluate whether glucagon-like peptide-1 re...

Ailawadi S, Murphy JE, Storandt MH, Mahipal A

Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have advanced the treatment of type 2 diabetes mellitus (T2DM), yet their association with cancer risk remains subject of ongoing research. Chronic pancreatitis (CP) is a well-established risk factor for pancreatic cancer, yet the ...

Toliver J, Wang J, Bhavsar J, Sullivan SD

Number needed to treat (NNT) and cost per event avoided (CPEA) are measures used to represent the clinical and economic value of chronic treatments and are commonly calculated based on primary endpoints from trials. This approach, although widely used, does not reflect the complete value of a tre...

Centor RM, Alkabbani W

Alvarez G, Huang A, Grody WW, Yazdani S

Alström syndrome (AS) is a rare autosomal-recessive ciliopathy caused by biallelic variants in ALMS1, with an incidence of 1 in 10,000 to 1 in 1,000,000 live births. We report a female diagnosed at age 5 with a previously unreported homozygous nonsense variant in ALMS1: c.4740C>G (p.Tyr15...

Leibnitz S, Winzeler B, Refardt J, Vogt DR, Sailer CO, Christ-Crain M et al.

Glucagon-like peptide-1 (GLP-1) plays an important modulatory role in sodium and water homeostasis. Recent studies demonstrated that long-term treatment with GLP-1 receptor agonists (RAs) reduces fluid intake and urine output. To the best of our knowledge, no direct effect of GLP-1 on vasopressin...

Riccioni G, Notarangelo C, Riccioni M, D'Orazio N

Cardiovascular diseases (CVDs) represent one of the leading causes of morbidity and mortality in patients with diabetes. However, a correct and effective glycaemic control obtained by pharmacologic interventions, such as the use the novel glucose-lowering agents, demonstrated efficacy in reducing...

Jeon M, Hong B, Ko HY, Song HJ, Kwak SH, Kim JH et al.

To compare the risk of osteoarthritis among patients with type 2 diabetes mellitus (T2DM) initiating glucagon-like peptide-1 receptor agonists (GLP-1RAs) versus dipeptidyl peptidase-4 inhibitors (DPP4Is).We conducted a nationwide cohort study applying a target trial emulation framework. From the ...

Tan X, Liang Y, Xie L, Harton J, Gutierrez C, Muhammad C et al.

This study aims to compare the risk of major adverse cardiovascular events (MACE) among United States individuals with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) treated with once-weekly semaglutide vs. dulaglutide.This was a retrospective cohort study using Optum's ...

Deameh MG, Ramez M, Rowaiee R, Bani Irshid BA, Mohamed H, Abdelshafi A et al.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are antidiabetic agents that also induce weight loss. Their widespread use has prompted investigation of potential benefits beyond glycemic control, including effects on male sexual and reproductive function. Emerging evidence suggests that the...